D-Wave Quantum (QBTS) and the pharmaceutical division of Japan Tobacco said Monday that they completed a joint proof-of-concept project adapting D-Wave's quantum computing technology and artificial intelligence for the drug discovery process.
The companies developed hybrid large language models that generated "more valid" molecules with a higher quantitative estimate of drug-likeness, compared with classical methods alone, they said.
Following the proof-of-concept project, Japan Tobacco's pharmaceutical division now plans to further advance development of quantum AI-driven drug discovery technology for molecular design, the companies said.
Price: 7.59, Change: +0.01, Percent Change: +0.15
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。